Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs MK-677 (Ibutamoren)
An educational, source-based comparison of GHRP-6 and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-6 | GHRP-6 and the ghrelin receptor: cardiometabolic effects | Cardiovascular Research | 2010 | Review of GH-independent cardioprotective signaling observed in animal models. |
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
Side-effect & safety grid
- Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- Not FDA-approved; banned by WADA.
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-6 vs MK-677 (Ibutamoren) — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: Growth hormone · Appetite vs Growth hormone · Oral.